Unleashing the immune system against cancer
Cyteph is an Australian biotechnology company developing off-the-shelf T cell and CAR T cell therapies, harnessing the power of the immune system to target and destroy solid tumours.
NEWS
Our innovative technology uses the natural ability of cytomegalovirus (CMV)-specific T cells to recognise and attack cancer cells; a novel approach to immunotherapy.
We use cells derived from healthy donors as the foundation of our therapies. This supports the development of off-the-shelf products that can be manufactured on a large scale, eliminating the need for costly and time-consuming T cell collection and engineering for each individual patient.
Our proprietary 'Cyt-ATTAC' platform leverages the unique properties of allogeneic CMV-specific T cells to enhance the safety, efficacy and persistence of Chimeric Antigen Receptor (CAR) T cell therapy, with the potential to develop multiple CAR T therapies with dual-targeting capabilities.
Our approach aims to overcome the current challenges of treating solid tumours with immunotherapy and to develop novel treatments for patients who currently have limited or no options available.
Cyteph is a spin-out company from QIMR Berghofer Medical Research Institute - a globally respected medical research institute based in Brisbane, Australia - at the forefront of developing and manufacturing cell therapies.
